Diagnostic Yield and Safety of Transbronchial Lung Biopsy Using Cryoprobes Versus Conventional Forceps. A Multicenter Study
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the diagnostic yield and safety of transbronchial lung biopsies (TBLB) with cryoprobe versus conventional forceps in patients with diffuse lung disease.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Active Comparator: Biopsy with Cryoprobes Transbronchial lung biopsy with a cryoprobe. |
Procedure: Transbronchial lung biopsy.
Transbronchial lung biopsy with cryoprobe and with conventional forceps.
|
Active Comparator: Biopsy with Conventional Forceps Transbronchial lung biopsy with conventional forceps. |
Procedure: Transbronchial lung biopsy.
Transbronchial lung biopsy with cryoprobe and with conventional forceps.
|
Outcome Measures
Primary Outcome Measures
- Diagnostic yield of transbronchial lung biopsy (TBLB) [24 months]
Comparing those TBLB obtained by cryoprobes versus conventional forceps (number of diagnosis with each technique).
Secondary Outcome Measures
- Histological quality of samples as defined the presence of alveolar units in each sample. Composite measure. [24 months]
The quality of samples are defined by the size, presence of artifacts and presence of alveolar units in each sample.
- Safety related to the procedure of the TBLB obtained by cryoprobe compared with conventional forceps assessed by chest radiography. [24 months]
Chest radiography after TBLB.
- Safety related to the procedure of the TBLB obtained by cryoprobe compared with conventional forceps assessed by control of bleeding. [24 months]
Control of bleeding during procedure.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
18 years old
-
Patients with diffuse lung disease candidate to study with transbronchial lung biopsy (TBLB).
-
Inform consent signed.
Exclusion Criteria:
-
FEV1 <40% of reference value.
-
Respiratory insufficiency (pO2 <60 mmHg or pCO2 >45 mmHg).
-
Use of anticoagulant therapy or presence of a coagulation (disorder abnormal platelets counts, international normalized ratio > 1.5).
-
Bullous emphysema.
-
Pulmonary arterial hypertension.
-
Hypersensitivity to anaesthetic and sedative drugs (lidocaine, midazolam, propofol, remifentanyl).
-
Psychiatric illness.
-
Comorbidities that could increase the risk of the TBLB.
-
Pregnancy.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Hospital de la Santa Creu i Sant Pau | Barcelona | Spain | 08025 |
Sponsors and Collaborators
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Hospital Universitario La Fe
- Germans Trias i Pujol Hospital
- Hospital General Universitario Santa Lucía
- Hospital Universitari de Bellvitge
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
- Complejo Hospitalario Universitario de Vigo
- University of Salamanca
- Hospital Universitario de Valladolid
Investigators
- Principal Investigator: Virginia Pajares, PhD, Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Study Documents (Full-Text)
None provided.More Information
Publications
- IIBSP-CRI-2014-05